Kalaris Therapeutics, Inc. (KLRS)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development (including 12, 13, 25 and 59 for a related party, respectively) | 8,440 | |||
| General and administrative (including 37, 48, 188 and 97 for a related party, respectively) | 3,816 | |||
| Total operating expenses | 12,256 | |||
| Loss from operations | -12,256 | |||
| Other income, net | 906 | |||
| Interest expense (including 0, 499, 1,384 and 577 for a related party, respectively) | - | |||
| Loss on extinguishment and on issuance of convertible promissory notes (including 0, 1,341, 169 and 2,134 for a related party respectively) | - | |||
| Change in fair value of tranche liability (including 331 for a related party for the six months ended june 30, 2025) | - | |||
| Change in fair value of derivative liabilities (including 0, 311, 1,165 and 311 for a related party, respectively) | - | |||
| Total other income (expense), net | 906 | |||
| Net loss | -11,350 | |||
| Net loss per share - basic | -0.61 | |||
| Net loss per share - diluted | -0.61 | |||
| Weighted-average common shares outstanding - basic | 18,701,286 | |||
| Weighted-average common shares outstanding - diluted | 18,701,286 | |||